Research Progress on Systemic Lupus Erythematosus Complicated with Infection

Open access


In recent years, in treatment standardization of systemic lupus erythematosus (SLE), infections and serious complications became the leading cause of death related to this disease, exceeding those of renal involvement and lupus encephalopathy. SLE coinfection is mainly related to defects in humoral immunity and cellular immunity, SLE disease activity, and doses of hormone and immune inhibitors.

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1 Fei Y Gan F Hou Y. Causes of death of systemic lupus erythematosus patients in the past twenty-five years. Chinese Journal of Rheumatology 201216(9):596-600.

  • 2 Mok M Wong S Chan T et al. Non-tuberculous mycobacterial infection in patients with systemic lupus erythematosus. Rheumatology 200746(2):280.

  • 3 Chen H Tsai WP Leu HS et al. Invasive fungal infection in systemic lupus erythematosus: an analysis of 15 cases and a liter-aturreview. Rheumatology 200746(3):539.

  • 4 Draborg AH Duus K Houen G. Epstein-Barr virus in systemic autoimmune diseases[J]. Clin Dev Immunol 20132013:535738.

  • 5 Barzilai O Sherer Y Ram M et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann N Y AcadSci 20071108: 567-577.

  • 6 Mcclain MT Poole BD Bruner BF et al. An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum 2006 54:360-368.

  • 7 Harley J B James JA. Epstein-Barr virus infection induces lupusautoimmunity. Bull NYU HospJt Dis 2006 64:45-50.

  • 8 Li Yi. EB Study of the relationship between Epstein-Barr virus infection and abnormal activation of B-lymphocytes in systemic lupus erythematosus. Chinese Journal of Rheumatology 2009 13(6):394-396.

  • 9 Wang L Wang J Pan L et al. The study on the possible pathogenesis of EBV latent membrane protein 1 in inducing systemic lupus erythematosus. Chinese Journal of Rheumatology 2011 15(10):707-709.

  • 10 Quan TE Roman RM Rudenga BJ et al. Epstein-Barr virus promotes interferon-alpha production by plasmacytoid dendritic cells. Arthritis Rheum 2010 62:1693.

  • 11 James JA Robertson JM. Lupus and Epstein-Barr. Curr Opin Rheumatol 2012 24:383-388.

  • 12 Larsen M Sauce D Deback C et al. Exhausted cytotoxic control of Epstein-Barr virus in human lupus. PLoS Pathog 2011 7:e1002328.

  • 13 Tattevin P Le Tulzo Y Minjolle S et al. Increasing incidence of severe Epstein-Barr virus-related infectious mononucleosis: surveillance study. J Clin Microbiol 2006 44(5): 1873-1874.

  • 14 Zhang X Feng X. Relevance of the Epstein Barr virus infection with systemic lupus erythematosus. Chinese Journal of clinicians 2013 7(14):6349-6354.

  • 15 Mai C Zhang D Ye R. Analysis of causes of death in 90 patients with systemic lupus erythematosus. Chinese Journal of Nephrology 1998 14(2):114-116.

  • 16 Hu J Li D. Analysis of factors associated with death in patient with systemic lupus erythrmatosus. Southern China Journal of Dermato-Venereology 2004 11(4):325-326.

  • 17 Chen X. Clinic analysis on 5l cases of SLE complicated with fugal infection. Beijing: Chinese Peking Union Medical College 2006.

  • 18 Jimper AH Knox Ks. An official American Thorack Society statement: treatment of fungal infections in adult pulmonary and critical care patients. Am J RespirCrit care Med 2011183(1):96-128.

  • 19 Szeto CC Kwan BC Lai FM et al. Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 200847(11):1678-1681.

  • 20 Chen HS Tsai WP Leu HS et al. Invasive fungal infection in systemic lupus erythematosus:an analysis of 15 cases and a literature review. Rheumatology 2007 46(3):539-544.

  • 21 Wu X Chen N. The clinical characteristics and early diagnosis of systemic lupus erythematosus complicated with infection. Chinese Journal of Practical Internal Medicine 2010 30(2):154-156.

  • 22 Ng W Chu C Yuen K et al. Lymphopenia at presentation is associated with increased risk of infections in patients with systemic lupus erythematosus. Q JM 2006 99(1):37.

  • 23 Jiang Y Zhao Y Wei W. Analysis of clinical characteristics of patients with systemic lupus erythematosus complicated with infection. Journal of Tianjin Medical University 2010 16(2):295-297.

  • 24 Juarez M Misischia R Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus scleroderma and polymyositis/dermatomyositis. Rheum Dis Clin North Am 2003 29(1):163-184.

  • 25 Li Zhijun Wang Cuilan Fan Xiaoyun et al. Clinic study on systemic lupus erythematosus complicated with bacterial and fugal infection. Chinese Journal of Rheumatology 2000 4(3):165-168.

  • 26 Lunch JP Martinez FJ. Pulmonary infection to match for transplant recipient. J Respir Dis 1993 14:528.

  • 27 Kim HA Yoo CD Baek HJ et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient-population. Clin Exp Rheumatol 1998 16(1):9-13.

  • 28 Sayarlioglu M. Tuberculosis in Turkish patients with systemic-lupus erythematosus: increased frequency of extrapulmonarylocalization. Lupus 200413(4):274-278.

  • 29 Mok MY Lo Y Chan TM et a1. Tuberculosis in systemic lupus erythematosus in an endemic area and the role of isoniazid prophylaxis during eorticosteroidtherapy. J Rheumatol 2005 32:609-615.

  • 30 Falagas ME Voidonikola PT Angelousi AG. Tuberculosis in patients with systemic rheumatic or pulmonary diseases treated with glueocorticosteroids and the preventive role ofisoniasid: a review of the available evidence. Int J Antimierob Agents 2007 30:477-486.

  • 31 Plakke MJ Jalota L Lloyd BJ. Pneumocystis pneumonia in a non-HIV patient on chronic corticosteroid therapy: a question of prophylaxis. BMJ Case Rep 2013. pii: bcr2012007912. doi:10.1136/bcr-20120007912.

  • 32 Mansharamani NG Balachandran D Vemovsky I et al. Peripheral blood CD4+T—lymphocyte counts during Pneumocystis carinii pneumonia in immanocompromised patients without HIV infection. Chest 2000118:712-720.

  • 33 Vogawa J Harigai M Nagasaka K et a1. Prediction of and prophylaxis against Pneumocystis pneumonia in patients with connective tissue diseases undergoing medium-or high dose corticosteroid therapy. Mod Rheumat 200515:91-96.

  • 34 He B Zhu Y. Application of procalcitonin in children with sepsis. Chinese Pediatric Emergency Medicine 2013 20(3):324-326.

  • 35 Yao Dongyun Huo Heshui. Rapid identification of procalcitonin in systemic lupus erythematosus activity and bacterial infection. Chinese Journal of clinical immunology and allergy 2014 221:227.

  • 36 Chang S Li G Wu Y et al. The value of calcitonin and high sensitive C reactive protein in the diagnosis of neonatal septicemia. Chinese Pediatric Emergency Medicine 2013 20(4):411-413.

  • 37 You H Qiu Y Wu L et al. The significance of CD64 index in the identification of systemic lupus erythematosus secondary infection and disease activity. Jiangsu Medicine Journal 2014 40(1):53-55.

  • 38 Zeevi A Lunz J. CylexImmuKnow cell function assay. Methods Mol Biol 2013 1034:343-351.

  • 39 Bhorade SM Janata K Vigneswaran WT et al. CylexImmu Know assay levels are lower in lung transplant recipients with infection. J Heart Lung Transplant 2008 2008: 990-994.

Journal information
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 159 67 3
PDF Downloads 75 40 2